Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Rx Zegerid deals blow to Santarus

This article was originally published in The Tan Sheet

Executive Summary

The proton pump inhibitor's originator is reducing its workforce by 37 percent, or about 120 employees, and ceasing promotion of Rx Zegerid in light of Prasco Labs' July 1 launch of a generic equivalent. A federal court in April ruled as invalid five patents held by Santarus on Zegerid (omeprazole/sodium bicarbonate), paving the way for generic competition (1"The Tan Sheet" April 19, 2010, In Brief). CEO Gerald Proehl said the layoffs were "an extremely difficult decision" for the San Diego-based firm, which had expected increased prescriptions for Zegerid following Merck/Schering-Plough's April launch of Zegerid OTC (2"The Tan Sheet" Nov. 23, 2009, In Brief). A Santarus spokeswoman said the firm still may receive an additional $37.5 million in Zegerid OTC sales milestones from the licensee

You may also be interested in...



Zegerid patents ruled invalid

A federal court in Delaware finds five patents on Zegerid prescription proton pump inhibitor invalid due to obviousness, likely also removing a hurdle for private label versions of Zegerid OTC (omeprazole/sodium bicarbonate), just launched by Merck/Schering-Plough. Par Pharmaceuticals filed the patent challenge after submitting abbreviated new drug applications to FDA in 2007 for generic Zegerid, the drug's originator Santarus said April 14. According to FDA's Orange Book, Merck has no period of market exclusivity for Zegerid OTC, approved for sale in December 2009 (1"The Tan Sheet" Dec. 7, 2009). A spokesman for Perrigo, which would likely be among the first to pursue a Zegerid OTC generic, said once patents are overcome, ANDA approval will take approximately two years

US FDA Puts All China Drug Inspections On Hold Due To Coronavirus Outbreak

February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.

Colgate Was Drawn To Hello Products’ Youthful Lifestyle Branding, And Now It Has A CBD Line

Successfully acquired by Colgate-Palmolive on 31 January, Hello quickly made a statement with the launch of a CBD oral-care range and its first go at lip care, CBD Vegan Lip Balm. Available exclusively through Ulta Beauty, the CBD products have the potential to score well with younger consumers interested in natural ingredients, eco-friendly packaging and, of course, cannabis-based innovations.

Topics

UsernamePublicRestriction

Register

PS104268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel